Skip to main content
SpringerLink
Log in

Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia?

  • Chronic Lymphocytic Leukemia (S O'Brien, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) shows a heterogeneous clinical course, which can be explained in part by prognostic factors. Most patients do not need treatment at the time of first diagnosis. The identification of prognostic factors is of major interest if strategies can be devised to treat patients according to their individual risk profile or biological subgroup. Currently, in spite of a wealth of prognostic factors, individualized treatment approaches in different genetic or risk groups are the exemption in CLL. This review summarizes the most important prognostic and predictive factors in CLL, with particular emphasis on factors affecting treatment decisions in clinical trials and routine practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88.

    Article  PubMed  CAS  Google Scholar 

  2. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975–80.

    Article  PubMed  CAS  Google Scholar 

  3. •• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74. This work presents the effect of the addition of rituximab to FC on response, PFS, and OS in a large, prospective clinical trial. Additionally, response and outcome are demonstrated according to different prognostic parameters.

    Article  PubMed  CAS  Google Scholar 

  4. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:602–609.

  5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.

    Article  PubMed  CAS  Google Scholar 

  6. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.

    PubMed  CAS  Google Scholar 

  7. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.

    Article  PubMed  CAS  Google Scholar 

  8. Letestu R, Levy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010;116(22):4588–90.

    Article  PubMed  CAS  Google Scholar 

  9. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia–what do we need to know? Nat Rev Clin Oncol. 2011;8(1):38–47.

    Article  PubMed  CAS  Google Scholar 

  10. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.

    Article  PubMed  CAS  Google Scholar 

  11. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.

    Article  PubMed  CAS  Google Scholar 

  12. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28–40.

    Article  PubMed  CAS  Google Scholar 

  13. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25(3):489–97.

    Article  PubMed  CAS  Google Scholar 

  14. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A. 1996;93(21):11837–41.

    Article  PubMed  CAS  Google Scholar 

  15. Isobe M, Emanuel BS, Givol D, et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320(6057):84–5.

    Article  PubMed  CAS  Google Scholar 

  16. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011;25(3):131–7.

    Article  PubMed  CAS  Google Scholar 

  17. • Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–9. This work analyses the response and survival of CLL patients with TP53 mutations after fludarabine-based chemotherapy.

    Article  PubMed  Google Scholar 

  18. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99(1):300–9.

    Article  PubMed  CAS  Google Scholar 

  19. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98(3):814–22.

    Article  PubMed  CAS  Google Scholar 

  20. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448–57.

    Article  PubMed  CAS  Google Scholar 

  21. • Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101–5. In this work, new recurrent mutations in CLL were identified with next-generation sequencing.

    Article  PubMed  CAS  Google Scholar 

  22. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389–401.

    Article  PubMed  CAS  Google Scholar 

  23. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011.

  24. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.

    Article  PubMed  CAS  Google Scholar 

  25. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011.

  26. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37–50.

    PubMed  CAS  Google Scholar 

  27. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–7.

    PubMed  CAS  Google Scholar 

  28. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.

    PubMed  CAS  Google Scholar 

  29. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99(6):2262–4.

    Article  PubMed  CAS  Google Scholar 

  30. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107(7):2889–94.

    Article  PubMed  CAS  Google Scholar 

  31. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609–14.

    Article  PubMed  CAS  Google Scholar 

  32. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–75.

    Article  PubMed  CAS  Google Scholar 

  33. Matrai Z, Lin K, Dennis M, et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood. 2001;97(6):1902–3.

    Article  PubMed  CAS  Google Scholar 

  34. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893–901.

    Article  PubMed  CAS  Google Scholar 

  35. • Wierda WG, O’Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009;27(10):1637–43. A multivariable model with characteristics predicting important clinical end points was developed in this article.

    Article  PubMed  CAS  Google Scholar 

  36. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):71–84.

    Article  PubMed  Google Scholar 

  37. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338(21):1506–14.

    Article  PubMed  CAS  Google Scholar 

  38. Ferrajoli A, Keating MJ, O’Brien S, et al. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2011;117(14):3182–6.

    Article  PubMed  CAS  Google Scholar 

  39. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110–8.

    Article  PubMed  CAS  Google Scholar 

  40. Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187–97.

    Article  PubMed  CAS  Google Scholar 

  41. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885–91.

    Article  PubMed  CAS  Google Scholar 

  42. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230–9.

    Article  PubMed  CAS  Google Scholar 

  43. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793–8.

    Article  PubMed  CAS  Google Scholar 

  44. Ding W, Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am Soc Hematol Educ Program. 2010;2010:90–2.

    Article  PubMed  Google Scholar 

  45. Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118(13):3525–7.

    Article  PubMed  CAS  Google Scholar 

  46. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6–14.

    Article  PubMed  CAS  Google Scholar 

  47. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349–55.

    Article  PubMed  CAS  Google Scholar 

  48. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26(31):5094–100.

    Article  PubMed  Google Scholar 

  49. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347(6):452–3.

    Article  PubMed  Google Scholar 

  50. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103(9):3278–81.

    Article  PubMed  CAS  Google Scholar 

  51. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27(35):6012–8.

    Article  PubMed  CAS  Google Scholar 

  52. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep. 2011;6(1):36–46.

    Article  PubMed  Google Scholar 

  53. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971–9.

    Article  PubMed  CAS  Google Scholar 

  54. Bottcher S, Stilgenbauer S, Busch R, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23(11):2007–17.

    Article  PubMed  CAS  Google Scholar 

  55. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2011; (in press).

  56. O’Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98(12):2657–63.

    Article  PubMed  Google Scholar 

  57. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18(6):1093–101.

    Article  PubMed  CAS  Google Scholar 

  58. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24(15):2337–42.

    Article  PubMed  CAS  Google Scholar 

  59. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010;28(29):4500–6.

    Article  PubMed  CAS  Google Scholar 

  60. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144(1):95–8.

    Article  PubMed  CAS  Google Scholar 

  61. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248–55.

    Article  PubMed  CAS  Google Scholar 

  62. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112(1):119–28.

    Article  PubMed  Google Scholar 

  63. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489–98.

    Article  PubMed  CAS  Google Scholar 

  64. Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine - Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. ASH Annual Meeting Abstracts. 2010;116(21):920.

  65. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111(1):446–52.

    Article  PubMed  CAS  Google Scholar 

  66. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912–20.

    Article  PubMed  Google Scholar 

  67. Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res. 2005;11(21):7757–63.

    Article  PubMed  CAS  Google Scholar 

  68. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23(15):3433–8.

    Article  PubMed  Google Scholar 

  69. • Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438–47. This trial demonstrates that patients with and without 17p- show similar survival after alloSCT.

    Article  PubMed  CAS  Google Scholar 

  70. Zenz T, Dreger P, Dietrich S, et al. Allogeneic stem cell transplantation can overcome the adverse prognostic impact of tp53 mutation in chronic lymphocytic leukemia (CLL): Results from the GCLLSG CLL3x Trial. ASH Annual Meeting Abstracts. 2010;116(21):2357.

    Google Scholar 

  71. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12–7.

    Article  PubMed  CAS  Google Scholar 

  72. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with Rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts. 2009;114(22):205.

    Google Scholar 

  73. Pettitt AR, Matutes E, Dearden C, et al. Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Haematologica. 2009;94(Suppl2):138. abstract 0351.

    Google Scholar 

  74. Parikh SA, Keating MJ, O’Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062–8.

    Article  PubMed  CAS  Google Scholar 

  75. Mauro FR, Molica S, Cortelezzi A, et al. Efficacy and safety of a first line combined therapeutic approach for young CLL patients with advanced or progressive disease stratified according to the biologic features: first analysis of the GIMEMA multicenter study LLC0405. ASH Annual Meeting Abstracts. 2010;116(21):2471.

    Google Scholar 

  76. Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Conflicts of Interest: L. Sellner: none; S. Dietrich: none; P. Dreger: none; H. Glimm: none; T. Zenz: Consultant for Celgene, GlaxoSmithKline, Boehringer-Ingelheim, and Trubion; payment for lectures from Roche and Celgene; payment related to patents from Boehringer-Ingelheim; travel or meeting expenses paid by Roche and Mundipharma.

Author information

Authors and Affiliations

  1. Department of Medicine V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Leopold Sellner, Sascha Dietrich, Peter Dreger & Thorsten Zenz

  2. Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany

    Hanno Glimm & Thorsten Zenz

Authors
  1. Leopold Sellner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sascha Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanno Glimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thorsten Zenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Zenz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sellner, L., Dietrich, S., Dreger, P. et al. Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia?. Curr Hematol Malig Rep 7, 3–12 (2012). https://doi.org/10.1007/s11899-011-0110-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-011-0110-1

Keywords

Search

Navigation